Novo Nordisk A/S $NVO Shares Sold by DE Burlo Group Inc.

DE Burlo Group Inc. cut its position in Novo Nordisk A/S (NYSE:NVO) by 22.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 374,660 shares of the company’s stock after selling 106,500 shares during the period. Novo Nordisk A/S makes up 2.3% of DE Burlo Group Inc.’s holdings, making the stock its 16th largest position. DE Burlo Group Inc.’s holdings in Novo Nordisk A/S were worth $19,063,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of NVO. Aurora Investment Counsel lifted its holdings in shares of Novo Nordisk A/S by 14.8% during the fourth quarter. Aurora Investment Counsel now owns 44,385 shares of the company’s stock worth $2,258,000 after purchasing an additional 5,706 shares during the period. Avidity Partners Management LP acquired a new position in Novo Nordisk A/S in the 4th quarter worth approximately $3,424,000. Brown Advisory Inc. increased its holdings in Novo Nordisk A/S by 5.8% in the 4th quarter. Brown Advisory Inc. now owns 113,301 shares of the company’s stock worth $5,765,000 after buying an additional 6,261 shares during the period. Aigen Investment Management LP purchased a new position in Novo Nordisk A/S during the 4th quarter worth approximately $861,000. Finally, Altrafin AG acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at approximately $8,913,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulators approved Novo Nordisk’s daily Wegovy pill, making it the first GLP-1 weight-loss tablet approved in the UK. That expands the company’s obesity franchise beyond injections and could open a new growth channel. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Several follow-up reports highlighted the UK approval as a milestone that could help Novo regain momentum in the obesity market and broaden access to Wegovy through private prescriptions. Novo Nordisk Wegovy pill becomes first daily GLP-1 weight-loss pill approved in the UK
• Positive Sentiment: Analysts also raised FY2026 EPS estimates slightly, signaling still-solid earnings expectations despite recent share-price weakness. Novo Nordisk A/S Trading Down 0.1%
• Neutral Sentiment: Some commentary on the “Wegovy pill” said the approval is encouraging but not yet enough to make certain investors buy, suggesting the market may want more proof of commercial impact before re-rating the stock. Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
• Negative Sentiment: Novo Nordisk disclosed an IT security incident involving unauthorized access to internal systems and potential data copying, which could pressure investor confidence even though the company said operations were not materially affected. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: Another report said some U.S. employers may drop GLP-1 obesity-drug coverage in 2027, a potential headwind for long-term demand and reimbursement for Wegovy and rival products. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on NVO. Sanford C. Bernstein began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price objective on the stock. Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Finally, Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a report on Tuesday, March 3rd. Four analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $43.90 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The business has a 50-day moving average price of $42.28 and a 200 day moving average price of $46.00. The firm has a market cap of $196.02 billion, a PE ratio of 10.31, a P/E/G ratio of 3.92 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion for the quarter. Sell-side analysts predict that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.